Aryx Therapeutics Stock Performance

ARYX
 Stock
  

USD 0.0005  0.00  0.00%   

The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. Let's try to break down what Aryx Therapeutics's beta means in this case. the returns on MARKET and Aryx Therapeutics are completely uncorrelated. Although it is important to respect Aryx Therapeutics historical returns, it is better to be realistic regarding the information on the equity's current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Aryx Therapeutics technical indicators, you can presently evaluate if the expected return of 0.0% will be sustainable into the future. Aryx Therapeutics right now shows a risk of 0.0%. Please confirm Aryx Therapeutics jensen alpha and semi variance to decide if Aryx Therapeutics will be following its price patterns.
  
Aryx Therapeutics Performance
0 of 100
Over the last 90 days Aryx Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Aryx Therapeutics is not utilizing all of its potentials. The new stock price disturbance, may contribute to short-term losses for the investors. ...more

Aryx Therapeutics Price Channel

Quick Ratio0.38
Fifty Two Week Low0.0001
Fifty Two Week High0.0350

Aryx Therapeutics Relative Risk vs. Return Landscape

If you would invest  0.05  in Aryx Therapeutics on May 18, 2022 and sell it today you would earn a total of  0.00  from holding Aryx Therapeutics or generate 0.0% return on investment over 90 days. Aryx Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Aryx Therapeutics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  

Aryx Therapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Aryx Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aryx Therapeutics, and traders can use it to determine the average amount a Aryx Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
ARYX
Based on monthly moving average Aryx Therapeutics is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aryx Therapeutics by adding it to a well-diversified portfolio.

About Aryx Therapeutics Performance

To evaluate Aryx Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Aryx Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Aryx Therapeutics Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Aryx Therapeutics stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Aryx Therapeutics's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Average Assets(1.55) (1.67) 
Return on Average Equity(5.81) (5.96) 
Return on Invested Capital(2.47) (2.66) 
Return on Sales(1.34) (1.44) 
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. Aryx Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 56 people.

Things to note about Aryx Therapeutics

Checking the ongoing alerts about Aryx Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Aryx Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Aryx Therapeutics Alerts

Equity Alerts and Improvement Suggestions

Aryx Therapeutics generated a negative expected return over the last 90 days
Aryx Therapeutics has some characteristics of a very speculative penny stock
Aryx Therapeutics has a very high chance of going through financial distress in the upcoming years
The company currently holds 11.57 M in liabilities. Aryx Therapeutics has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aryx Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aryx Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aryx Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aryx Therapeutics to invest in growth at high rates of return. When we think about Aryx Therapeutics' use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 19.72 M. Net Loss for the year was (18.33 M) with profit before overhead, payroll, taxes, and interest of 0.
Aryx Therapeutics currently holds about 2.95 M in cash with (20.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Aryx Therapeutics has a very weak financial position based on the latest SEC disclosures
Please continue to Trending Equities. Note that the Aryx Therapeutics information on this page should be used as a complementary analysis to other Aryx Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Aryx Therapeutics Stock analysis

When running Aryx Therapeutics price analysis, check to measure Aryx Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aryx Therapeutics is operating at the current time. Most of Aryx Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aryx Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aryx Therapeutics' price. Additionally, you may evaluate how the addition of Aryx Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Is Aryx Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aryx Therapeutics. If investors know Aryx Therapeutics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aryx Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
237.6 K
Return On Assets
-0.75
The market value of Aryx Therapeutics is measured differently than its book value, which is the value of Aryx Therapeutics that is recorded on the company's balance sheet. Investors also form their own opinion of Aryx Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aryx Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aryx Therapeutics' market value can be influenced by many factors that don't directly affect Aryx Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aryx Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Aryx Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aryx Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.